🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 86 of 857 · Phase 3 first, then by program name

  1. Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Pomalidomide, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, VELCADE 3.5 mg powder for solution for injection, Imnovid 3 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Privigen 100 mg/ml solution for infusion, teclistamab, Pomalidomide, Dexamethason 4 mg JENAPHARM®, Fortecortin® 2 mg Tabletten, teclistamab, Pomalidomide, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infu

    Janssen-Cilag International N.V.

    Relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  2. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Lacuna Pharma Pty Ltd

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  3. Imnovid 3 mg hard capsules, DEXAMETHASONE , Venetoclax, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    R/R Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  6. Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada

    Lacuna Pharma Pty Ltd

    Impetigo

    phase 3 small molecule active

    1 trial

  7. In-person Cognitive Behavioral Therapy of Insomnia

    United Therapeutics Europe Ltd

    Insomnia

    phase 3 other completed

    1 trial

  8. Inactivated COVID-19 Vaccine

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab completed

    4 trials

  9. Inactivated Poliomyelitis Vaccine (Sabin strains)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Poliomyelitis

    phase 3 mab completed

    2 trials

  10. Inclisiran

    Novartis Pharmaceuticals

    Familial Hypercholesterolemia - Heterozygous

    phase 3 small molecule completed

    1 trial

  11. IncobotulinumtoxinA (XEOMIN®)

    Camp4 Therapeutics Corp

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  12. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  13. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  14. Indiplon

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  15. Individualized Elective Neck Irradiation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 other active

    1 trial

  16. Induction Chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  17. Infacort®

    NEUROCRINE BIOSCIENCES INC

    Adrenal Insufficiency

    phase 3 small molecule completed

    4 trials

  18. Infanrix hexa™

    GlaxoSmithKline

    Poliomyelitis

    phase 3 mab completed

    1 trial

  19. Infanrix-IPV+Hib™

    GlaxoSmithKline

    Acellular Pertussis

    phase 3 mab completed

    1 trial

  20. InfectoScab® 5 % Crème, Permethrin, DRIPONIN 3 mg Tabletten

    Alphapharm Pty Ltd

    Scabies

    phase 3 small molecule active

    1 trial

  21. Infigratinib

    BridgeBio Oncology Therapeutics

    Upper Tract Urothelial Carcinomas

    phase 3 small molecule terminated

    1 trial

  22. Infigratinib 0.25 mg/kg/day

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 3 small molecule completed

    1 trial

  23. Infliximab + methotrexate (IFX + MTX)

    Universal Integrated

    Arthritis, Psoriatic

    phase 3 small molecule completed

    1 trial

  24. Infliximab Increased Frequency

    Universal Integrated

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources